The question remains open whether 1,25-dihydroxyvitamin D3 treatment is feasible in cancer stages and metastasis being distinct in high TRPV6 expression, or, otherwise, in the prostate cancer cells biopsies still responsive to 1,25-dihydroxyvitamin D3 treatment by overexpressing TRPV6. Here, TRPV6 is linked to prostate carcinoma.